Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Gene Variations Can Predict Radiation-Induced Toxicity Risk

By BiotechDaily International staff writers
Posted on 04 Aug 2014
Key genetic variants may affect how cancer patients respond to radiation treatments, according to new research. Scientists discovered that differences in the TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1) gene are associated with a greater risk for radiation-fueled side effects in prostate cancer patients, which include impotence, diarrhea, and incontinence.

These findings, published July 2014 in Nature Genetics, are based on a genome-wide association study, a type of study in which researchers studied a variety of genetic variants to see if any of them are tied to a specific type of complication, which could sometimes appear years after treatment was completed.

“Our findings, which were replicated in two additional patient groups, represent a significant step towards developing personalized treatment plans for prostate cancer patients,” said Barry S. Rosenstein, PhD, professor, radiation oncology, genetics and genomic sciences, Icahn School of Medicine at Mount Sinai (New York, NY, USA), the lead Mount Sinai investigator on the study. “Within five years, through the use of a predictive genomic test that will be created using the data obtained in the recent study, it may be possible to optimize treatment for a large number of cancer patients.”

For the study, Dr. Rosenstein and his colleagues obtained blood samples from nearly 400 patients who were receiving radiotherapy treatment for prostate cancer. The blood samples were screened for roughly one million genetic markers, and each patient was monitored for at least two years to monitor incidents of side effects from the radiation. Data analysis revealed which genetic markers were consistently associated with the development of complications following radiotherapy.

“The next step is to validate the results, and see if the same markers predict similar outcomes in patients with other forms of cancer,” said Dr. Rosenstein. Using the genomic test being developed, treatment plans can be adjusted to curtail adverse effects thereby allowing for an improved quality life for many cancer survivors.

Related Links:

Icahn School of Medicine at Mount Sinai



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.